The recent EU-US trade deal has significant implications for the pharmaceutical industry, particularly in terms of tariff rates on generic and branded pharmaceutical products imported from the EU into the US. While generic pharmaceuticals, which constitute a substantial portion of US prescriptions, will now face effectively zero or close to zero tariffs, branded pharmaceuticals will be subject to a blanket 15% tariff rate. This agreement follows President Trump’s decision to impose a 15% import tariff on EU goods, prompting concerns and uncertainties within the industry.
The Most Favoured Nation (MFN) tariff rate, a standardised non-discriminatory tariff applied to all trading partners unless otherwise negotiated, will now be extended to generic pharmaceuticals and their active pharmaceutical ingredients (APIs) under the EU-US trade deal. Although the exact MFN rate has not been disclosed by the Trump Administration, the European Commission has indicated that it will likely be close to zero once it takes effect in September 2025. This move aims to streamline trade relations between the EU and the US, impacting the supply chains of pharmaceutical products significantly.
Despite the positive outlook for generic pharmaceuticals, concerns have been raised regarding the impact on branded pharmaceuticals. With a 15% tariff imposed on these products and their constituents, there are fears of potential disruptions in the pharmaceutical supply chain, given that the EU supplies a significant portion of the APIs used in US-prescribed branded pharmaceuticals. However, the Trump Administration has assured that tariffs will not exceed 15%, offering some stability for European-based pharma companies amidst the evolving trade landscape.
GlobalData analysts have projected potential losses of $13bn to $19bn for the pharmaceutical industry due to the trade deal. While the 15% tariff rate is more favorable compared to the previously threatened 200% tariffs, uncertainties persist regarding the overall impact on the industry. The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed concerns about the future implications of the trade deal, particularly in terms of patient access to innovative treatments and the diversion of funds from medical research.
In response to these challenges, the EFPIA has called for exemptions on innovative medicines to safeguard patient interests and uphold the competitiveness of the EU pharmaceutical sector. Industry experts, such as Liam Maddison from Syneos Health, have highlighted the risks associated with tariffs, including potential cost increases for patients, disruptions in the supply chain, and shifts in global pricing dynamics. As the trade dynamics evolve, companies must prepare for potential market access discussions and navigate the changing tariff landscape effectively to mitigate risks and ensure continuity in operations.
Overall, the EU-US trade deal has raised significant concerns within the pharmaceutical industry, particularly regarding the varying tariff rates applied to generic and branded pharmaceuticals. While efforts are being made to address these concerns and mitigate potential disruptions, uncertainties persist regarding the long-term impact on patient access, research funding, and market dynamics. Stakeholders in the pharmaceutical sector must stay vigilant, adapt to the changing trade environment, and advocate for policies that support innovation, patient access, and industry sustainability.
Key Takeaways:
– The EU-US trade deal introduces distinct tariff rates for generic and branded pharmaceuticals, with generic products facing close to zero tariffs and branded products subject to a 15% tariff.
– Concerns have been raised by industry stakeholders, such as the EFPIA, regarding the potential impact on patient access to innovative treatments and research funding diversion.
– Companies must proactively assess and address the implications of the trade deal on their operations, supply chains, and market access strategies to navigate the evolving tariff landscape effectively.
– Collaboration between industry players, policymakers, and regulatory bodies is crucial to ensure a balanced approach that supports innovation, patient interests, and the sustainability of the pharmaceutical sector.
Read more on pharmaceutical-technology.com